InsidersTradesSigma
Follow the 대성미생물 stock price and the full directors' dealings record of the company, a listed issuer based in South Korea. Shares are listed on the KR market, under the supervision of DART (FSS). Operating in the Health Care sector, 대성미생물 has published 19 reports. Market capitalisation: €24.6bn. The latest transaction was reported on 4 June 2026 (Purchase). Among the most active insiders: 최승훈. All data is free.
19
Insider Decl.
n/a
Thresholds
€17m
15 ops.
Buy Volume
€7m
1 ops.
Sell Volume
33Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 19,493 of 29,065 companies
40.6
score / 100
Value52
Quality29
FCF yld4.4%
Earn yld2.5%
EV/EBITDA12.6x
ROE1.0%
Gross mgn25%
Net mgn2.3%
Debt/EBITDA5.7x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 4 June 2026
Declarations19 total
19 of 19 declarations
关于 대성미생물
대성미생물是一家专注于健康和制药领域的公司，在XKRX市场上市。该公司专注于微生物产品的开发和生产。